Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Идиопатический легочный фиброз

Список литературы

  1. Raghu G., Collard H.R., Egan J.J. and ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
  2. Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
  3. Travis W.D., Costabel U., Hansell D.M. and ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
  4. Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet 2006; 79: 149–154.
  5. Allen R.J., Porte J., Braybrooke R. et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med 2017; 5 (11): 869–880.
  6. Авдеев С.Н. Идиопатический фиброз легких: новая парадигма. Тер Архив 2017; 89(№ 1): 112-122. DOI: 10.17116/terarkh2017891112-122
  7. Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc Am Thorac Soc. 2006; 3: 293–298.
  8. Bedard Methot D., Leblanc E., Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest 2019; 155 (1): 33–43.
  9. Garcıa-Sancho Figueroa M.C., Carrillo G., Pérez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med 2010; 104: 305–309.
  10. Oldham J.M., Kumar D., Lee C. et al. Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2015; 148 (3): 692–700.
  11. Stock C.J., Sato H., Fonseca C. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68 (5): 436–441.
  12. El-Chemaly S., Ziegler S.G., Calado R.T. et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest 2011; 139 (5): 1203-1209.
  13. Tsang A.R., Wyatt H.D., Ting N.S. et al. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell 2012; 11 (3): 482–490.
  14. Fukuhara A., Tanino Y., Ishii T. et.al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur Respir J 2013; 42 (6): 1757-1759.
  15. Kropski J.A., Mitchell D.B., Markin C. et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 2014; 146 (1): e1–e7.
  16. Alder J.K., Stanley S.E., Wagner C.L. et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2015; 147 (5): 1361–1368.
  17. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М., Коган Е.А., Самсонова М.В., Сперанская А.А., Тюрин И.Е., Черняев А.Л., Черняк Б.А., Черняк А.В., Шмелев Е.И. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология 2016; 26(№4): 399-419.
  18. Raghu G., Chen S., Yeh W., Maroni B., Li Q., Lee Y., et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014; 2: 566–572.
  19. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
  20. Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967–972.
  21. Nalysnyk L., Cid-Ruzafa J., Rotella P. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355–361.
  22. Richeldi L, Rubin A, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine 2015; 13: 237.
  23. Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198 (5): e44-e68.
  24. Lynch D.A., Sverzellati N., Travis W.D. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018; 6(2): 138-153.
  25. George R.B., Light R.W., Mattay M.A., Mattay R.A. (eds.). Chest Medicine: Essentials Of Pulmonary And Critical Care Medicine. 5-th edition, LWW, 2005; 238-244.
  26. Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med, 2016; 194:265–275.
  27. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517–525.
  28. King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171–118.
  29. Авдеев С.Н. Обострение идиопатического легочного фиброза. Пульмонология 2018; 28(4): 469–482. DOI: 10.18093/0869-0189-2018-28-4-469-482
  30. Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22: 821–826.
  31. Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143–150.
  32. Rajala K., J.T. Lehto, Sutinen E., Kautiainen H., Myllärniemi M., Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis // ERJ Open Research Oct 2017, 3 (4) 00084-2017; DOI: 10.1183/23120541.00084-2017
  33. Ley B., Ryerson C.J., Vittinghoff E., Ryu J.H., Tomassetti S., Lee J.S., Poletti V., Buccioli M., Elicker B.M., Jones K.D., King T.E. Jr., Collard H.R. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.
  34. Sgalla G., Walsh S.L.F., Sverzellati N. et al. "Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm Med. 2018;18(1):103. doi: 10.1186/s12890-018-0670-0.
  35. Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
  36. Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962–969.
  37. Mathieson J.R., Mayo J.R., Staples C.A., Muller N.L. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989;171:111–116.
  38. Remy-Jardin M., Campistron P., Amara A. et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J Comput Assist Tomogr 2003; 27: 266–273.
  39. Bankier A.A., O’Donnell C.R., Boiselle P.M. Quality initiatives. Respiratory instructions for CT examinations of the lungs: a hands- on guide. Radiographics 2008; 28: 919–931.
  40. Kim M., Lee S.M., Song J.W. et al. Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. Eur J Radiol 2017; 91: 66–70.
  41. Gotway M.B., Lee E.S., Reddy G.P. et al. Low-dose, dynamic, expiratory thin-section CT of the lungs using a spiral CT scanner. J Thorac Imaging 2000; 15: 168–172.
  42. Lynch D.A., Godwin J.D., Safrin S. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488–493.
  43. Remy-Jardin M., Giraud F., Remy J. et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693–698.
  44. Silva C.I., Müller N.L., Lynch D.A. et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008; 246: 288–297.
  45. Raghu G., Mageto Y.N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116: 1168–1174.
  46. Chung J.H., Chawla A., Peljto A.L. et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 2015; 147: 450–459.
  47. Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586–593.
  48. Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186-196.
  49. Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 1209–1215.
  50. Enright P.L. The six-minute walk test. Respir Care 2003; 48: 783–785.
  51. Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084–1090.
  52. du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
  53. Caminati A., Bianchi A., Cassandro R. et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103:117-123.
  54. Lederer D.J., Arcasoy S.M., Wilt J.S. et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659-664.
  55. Dowman L., Hill C.J., Holland A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10:CD006322.
  56. Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996; 110 (4):1058–1067.
  57. Hanson D., Winterbauer R.H., Kirtland S.H., Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108 (2): 305–310.
  58. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161 (4 I): 1172–1178.
  59. Raghu G., Depaso W.J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144 (2): 291–296.
  60. Flaherty K.R., Toews G.B., Lynch J.P. et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278–282.
  61. Martinez F.J., Arbor A., Cornell W. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-2101.
  62. Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897–1901.
  63. Tomioka H., Kuwata Y., Imanaka K. et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 2005; 10: 449–455.
  64. Oldham J.M., Ma S.-F., Martinez F.J. et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015; 192: 1475–1482.
  65. Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229–2242.
  66. Raghu G., Anstrom K.J., King T.E. Jr. et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977.
  67. Raghu G,. Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003.
  68. Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88–95.
  69. Lee J.S., Collard H.R., Anstrom K.J. et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1 (5): 369–376.
  70. Tran T., Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J 2018; 51: 1800376.Di Mar
  71. Di Martino E., Provenzani A., Vitulo P., Polidori P. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis. Ann Pharmacother 2021; 55 (6): 723-731. doi: 10.1177/1060028020964451.
  72. Lancaster L., Crestani B., Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res 2019;6(1):e000397. doi: 10.1136/bmjresp-2018-000397.
  73. Skandamis A., Kani C., Markantonis S.L., Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J Drug Assess. 2019;8(1):55-61. doi: 10.1080/21556660.2019.1597726.
  74. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365 (12): 1079–1087.
  75. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2071–2082.
  76. Crestani B., Huggins J.T., Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med 2019; 7 (1): 60-68.
  77. Richeldi L., Cottin V., du Bois R.M. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS Trials. Respir Med 2016; 113: 75-79.
  78. Авдеев С.Н. Новые возможности терапии идиопатического легочного фиброза. Пульмонология 2017; 27(№4): 502-514.
  79. Авдеев С.Н., Трушенко Н.В. Антифибротическая терапия идиопатического легочного фиброза. Медицинский Совет 2018; №15: 131-136.
  80. Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760–1769.
  81. King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2083–2092.
  82. Nathan S.D., Albera C., Bradford W.Z. et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2017; 5 (1): 33–41.
  83. Richeldi L., Cottin V., Flaherty K.R.et al. Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine 2014; 108 (7): 1023-1030. https://doi.org/10.1016/j.rmed.2014.04.011
  84. .Nathan S.D., Costabel U., Albera C. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44-51. doi: 10.1016/j.rmed.2019.04.016.
  85. Birring S.S., Kavanagh J.E., Irwin R.S. et al. Treatment of Interstitial Lung Disease associated cough: CHEST guideline and expert panel report. Chest 2018; 154 (4): 904-917.
  86. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–398.
  87. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.
  88. Faverio P., De Giacomi F., Sardella L. et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm Med. 2018;18(1):70. doi: 10.1186/s12890-018-0643-3.
  89. Dreher M., Ekkernkamp E., Schmoor C. et al. Pulmonary rehabilitation and noninvasive ventilation in patients with hypercapnic interstitial lung disease. Respiration. 2015;89(3):208-13. doi: 10.1159/000369862
  90. Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001; 120: 213–219.
  91. Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11: 117–122.
  92. Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration 2010; 79: 209–215.
  93. Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469–475.
  94. Hanada M., Kasawara K.T., Mathur S., Rozenberg D. et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020; 12 (3): 1041-1055. doi: 10.21037/jtd.2019.12.27.
  95. King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171–177.
  96. Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830–836.
  97. Zieliński M., Sitek P., Ziora D. Idiopathic pulmonary fibrosis coexisting with lung cancer - a review. Adv Respir Med 2018; 86 (6): 319–326.
  98. Karampitsakos T., Tzilas V., Tringidou R. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2017; 45:1-10.
  99. Vancheri C. Cancer. In: Costabel U., Crestani B., Wells A. Idiopathic Pulmonary Fibrosis. ERS monograph, 2016, 71: 151-158.
  100. Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895–900.
  101. Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372–376.
  102. Collard H.R., Anstrom K.J., Schwarz M.I., Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897–899.
  103. Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–607.
  104. Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med 2008; 102: 1015–1020.
  105. Fulton B.G., Ryerson C.J. Managing comorbidities in idiopathic pulmonary fibrosis. International Journal of General Medicine 2015: 8: 309–318.
  106. Raghu G., Yang S.T., Spada C., et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794-800.
  107. Linden P.A., Gilbert R.J., Yeap B.Y., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131: 438-446.
  108. Lee J.S., Ryu J.H., Elicker B.M., et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-1394.
  109. Savarino E., Bazzica M., Zentilin P., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179: 408-413.
  110. Cano-Jiménez E., Hernández González F., Peloche G.B. Comorbidities and complications in idiopathic pulmonary fibrosis. Med Sci 2018; 6: 71.
  111. Kreuter M., Brunnemer E., Ehlers-Tenenbaum S. et a. Other comorbidities. In: Costabel U., Crestani B., Wells A. Idiopathic Pulmonary Fibrosis. ERS monograph, 2016, 71: 174-185.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*